Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis
Authors:
- 3 July 2020
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (6) , 2129-2134
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD AndersonJournal for ImmunoTherapy of Cancer, 2018
- Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodiesAnnals of Oncology, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2016
- Systematic review: colitis associated with anti‐CTLA‐4 therapyAlimentary Pharmacology & Therapeutics, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProceedings of the National Academy of Sciences of the United States of America, 2003